ZHONGSHENGYAOYE(SZ:002317) Shang Hai Zheng Quan Bao·2025-09-18 20:31Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management, allowing up to RMB 180 million to be invested in safe, principal-protected financial products to enhance fund efficiency and returns [1][26][42]. Group 1: Board Meeting Resolutions - The board meeting was held on September 18, 2025, with all nine directors present, and the decision to use idle funds was made unanimously [1][3]. - The resolution allows for the investment of up to RMB 180 million in structured deposits and large certificates of deposit, ensuring that the investment does not affect the normal operation of the fundraising projects [2][26]. Group 2: Cash Management Details - The cash management period is set for twelve months from the date of the board's approval, with the ability to roll over the funds within the specified limit [2][36]. - The investment products chosen for cash management are low-risk, principal-protected options, ensuring high safety and liquidity [33][34]. Group 3: Financial Overview - The company raised a total of approximately RMB 598.57 million from a recent stock issuance, with a net amount of RMB 590.20 million after deducting issuance costs [27][30]. - As of June 30, 2025, the company has utilized RMB 342.33 million of the raised funds, with some funds remaining idle due to project timelines [30][31]. Group 4: Monitoring and Compliance - The board and supervisory committee have confirmed that the cash management plan complies with relevant regulations and does not harm shareholder interests [43][44]. - The company will ensure timely disclosure of information related to the cash management activities as per regulatory requirements [39][44].